New molecular entity roxadustat shows non-inferiority to darbepoetin alfa for anaemia in non-dialysis dependent adults with stage 3-5 chronic kidney disease

Roxadustat, a first-in-class oral inhibitor of hypoxia-inductible factor (HIF) prolyl hydroxylase (PH), was non-inferior to darbepoetin alfa in haemoglobin levels during first 24 weeks of treatment. A marketing application is currently being reviewed by European Medicines Agency.


Biospace Inc.